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Acute myocardial infarction (AMI) is the leading cause of death in developed countries;1 however, in-hospital mortality 
from this cause has been declining over the last three 
decades.2 This reduction in mortality coincides with 
the improvement in health and living standards 
and with new treatments like thrombolysis and 
new interventions like percutaneous coronary 
intervention (PCI) and coronary artery bypass 
grafting (CABG).  Secondary and primary prevention 
strategies have contributed significantly and the 
age-adjusted mortality is expected to continue to 
decline with further improvements in treatments, 
better uptake of primary and secondary prevention 
strategies and also with further improvement in our 
ability to recognise this challenging disease very 
early in its course. The success of treatment rests on: 
1) identification of patients in the very early stages of 
AMI; 2) implementation of treatment to recanalise 
the occluded artery; 3) access to early defibrillation 
and 4) admission to properly monitored coronary 
care or intensive care units (CCU or ICU) for the 
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 ركبلما جلاعلاو صيخشتلا في ةمصاولا ةيبلقلا تاملاعلا مادختسا
ةدالحا ةيبلقلا  ةمزلاتلما نم نوناعي نيذلا ىضرملل
سكوف ثيك ،يداهلا ظيفح
 .ةيبطلا  ةياعرلا  بلط ىلع ضيرلما  ربجي  يذلا  اثودح رثكلأا  ببسلا  نوكي  ام  ابلاغ  هنأ  نم  مغرلا  ىلع  ةيعون  ريغ  ىوكش  ردصلا  ملأ  دعي  :صخللما
 ريغ بلقلا طيطختو يريرسلا خيراتلا ىلع ينبلماو ايلاح عبتلما صيخشتلا ماظن .ةدالحا ةيبلقلا ةمزلاتلما نم نوناعي ىضرلما ءلاؤه نم ةريغص ةعومجم
 يفو .ةبسانم ريغ اًصوحف وأ ةيودأ وأ ةياعر اوقلتي نأ وأ ،ةبسانلما ريغ ماسقلأا ىلإ ىضرلما لاخدإو ئطالخا صيخشتلا ىلإ نايحلأا ضعب يف يدؤي دقو ،يفاك
 ةيبلقلا ةمزلاتلما نم نوناعي نيذلا ىضرلما نم ليلق .اهئاطعإ مدع ىتح وأ ةيرورضلا ةيودلأا ءاطعإ ريخأت ىلإ يدؤي اذهو صيخشتلا رخأتي ىضرلما ضعب
 نم ريبك ددع لاخدإ ىلإ اضيأ يدؤي دق اذه صيخشتلا ماظن نأ امك .ةينوناقو  ةيحص راطخأ هيلع بترتي دق امم ،أطخ ئراوطلا نم مهجارخإ متي دق ةدالحا
 لكشب ردصلا ملاآ نم نوناعي نيذلا ىضرلما جلاعو صيخشتل يلالحا ماظنلا ريوطت نكيم .عاد نودب ىفشتسلما ىلإ ةيبلق ضارمأ نم نوناعي لا نيذلا ىضرلما
 تاملاعلا لوانتي لاقلما اذه .ةدالحا ةيبلقلا ةطللجا نع ادج ركبلما فشكلل ةلسلستلما ةمصاولا ةيبلقلا تاملاعلا صحف ماظن لاخدإ قيرط نع ريبك
 زينياك ينتايرك ،(ةيلعاف و  ةلتك)  غامدلاو  ةلضعلا  زينياك ينتايرك ،زينياك ينتايرك لثم بلقلا  ةلضع فلت  صيخشتل ايلاح ةرفوتلما  ةمصاولا  ةيبلقلا
.(أ ) بلقلا يننبورتو (ت) بلقلا يننبورت ،ينبولجويام ،ينهدلا بلقلا ضملح طبارلا ينتوربلا ،(يلثم)  غامدلاو ةلضعلا
.ردصلا ملأ ،ةداح ةيبلق ةطلج ،ةدالحا ةيبلقلا ةمزلاتلما ،ةمصاولا ةيبلقلا تاملاعلا :تاملكلا حاتفم
abstract: Chest pain is a non-specific complaint and is the most frequent reason for patients seeking urgent 
medical attention. A small group of these patients will have acute coronary syndromes (ACS). The current diagnostic 
and triage systems based on clinical history and electrocardiograms are insufficient. They may result in some of these 
patients being misdiagnosed and being admitted to the wrong units or receiving inappropriate care, treatment and 
investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of 
essential early treatment. A few patients with ACS may be inadvertently discharged from the emergency department 
leading to serious health and legal implications. These systems also result in the unnecessary admission of a substantial 
number of patients without ACS. The triage and management of patients with chest pain can be considerably improved 
by implementation of serial cardiac markers testing that can identify ACS in the very early stages of presentation. 
This review article will discuss the currently available markers of myocardial damage such as  creatine kinase (CK), 
creatine kinase muscle and brain (CK-MB) (mass and activity), CK-MB isoforms, heart-type fatty acid-binding protein, 
myoglobin, cardiac troponin T, and cardiac troponin I.
Keywords: Cardiac markers; Acute coronary syndromes; ACS; Acute myocardial infarction; AMI; Non-ST elevation 
myocardial infarction;  NSTEMI; Chest pain.
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detection and treatment of complications. 
The diagnosis of AMI was previously based on 
the criteria set by the World Health Organization 
(WHO) and had to include two of the following: 1) 
typical history of prolonged ischaemic chest pain; 
2) presence of typical acute ischaemic changes 
on the admission electrocardiograms (ECG); 3) 
typical rise and fall of cardiac enzymes in blood.3 
This old definition has recently been changed with 
the publication of a new definition of myocardial 
infarction by The Joint European Society of 
Cardiology/American College of Cardiology (ESC/
ACC) Committee, which redefines myocardial 
infarction (MI) according to cardiac markers as 
follows: 1) an increase in cardiac troponin cTnI, 
cTnT exceeding the decision limit (99th percentile 
of the value for a reference control group) on at 
least one occasion; 2) an increase in creatine kinase 
muscle and brain (CK-MB), preferably CK-MB 
mass exceeding the decision limit (99th percentile of 
the value for a reference control group) on at least 
two occasions with a rise and fall pattern, or greater 
than twice the upper limit of the reference range on 
one occasion. Within this definition, acute coronary 
syndromes (ACS) are classified into ST and Non-ST 
elevation. ST elevation ACS is further classified into 
Q-wave and non Q-wave MI. Non-ST elevation MI 
(with cardiac marker elevation) is also classified into 
Q-wave and non Q-wave MI. Non-ST elevation 
ACS without cardiac markers elevations is called 
unstable angina.4
The very early diagnosis of AMI can be 
a challenging task for many physicians in an 
emergency department. When a typical history is 
present, it helps to orient the clinician to the right 
diagnosis, but its absence by no means rules it out. 
This is often the case in a significant proportion of 
patients in whom the history is either atypical or 
absent. Diabetic, hypertensive, and elderly patients 
often have silent AMI. In these cases AMI may 
go unnoticed or may produce atypical symptoms 
such as hypotension, breathlessness, syncope, or 
arrhythmias.5 The ECG is an important tool for 
detecting AMI, but it lacks sensitivity and as many 
as 30-50% of patients may initially present with 
normal or non-diagnostic ECG.6 The ECG has an 
overall diagnostic sensitivity for AMI of 70-81%;7 
however, when changes typical of AMI are present 
on the admission ECG (ST elevation and new 
Q-wave) they are highly specific and have a very 
high positive predictive value for the diagnosis of 
AMI. Cardiac markers are formidable tools for the 
diagnosis of AMI.8 
Characteristic Features of 
Biochemical Markers of 
Myocardial Injury
The ideal characteristics of a marker of myocardial 
injury are: 1) it should be abundant in the 
myocardium and not present in other tissues. This 
gives it a high specificity for the myocardium and 
reduces the rate of false positive results; 2) it should 
have a high concentration in the myocardium and a 
low or undetectable concentration in the blood in 
the absence of disease. This gives it a high sensitivity 
so that the release of only a small amount can be 
readily detected thereby reducing the rate of false 
negatives; 3) it should be released completely and 
quickly when myocardial damage occurs. This 
will allow its utilisation for the early detection 
and quantification of injury; 4) it should persist 
in the circulation to give a convenient diagnostic 
window, but not so long as to prevent the detection 
of complications such as early re-infarction, and 
5) the assay must have a high analytical sensitivity 
and specificity and a short turn around time, so that 
results could be obtained fast enough to influence 
the decision-making process regarding patients’ 
triage and management.
Biochemical Markers and 
Early Detection of Acute 
Myocardial Infarction
Cardiac markers play an important role in the 
detection of AMI when the patient’s history and 
ECG are non-diagnostic or equivocal.9 Diagnosing 
AMI early (i.e. within 6 hours after symptom onset) 
is difficult, because some time must elapse after 
symptom onset for markers to exceed values above 
the reference range. The diagnosis of AMI based 
only on one single value at presentation or soon 
after admission is unreliable, and serial sampling 
is the most effective method. The sensitivity and 
specificity of cardiac markers for the early diagnosis 
of AMI is influenced by several factors such as:
1. Time of presentation: Early presentation after 
symptom onset is likely to show a relatively 
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increased sensitivity for markers like myoglobin, 
which is released very early in the course of AMI, 
and less sensitivity for markers like CK-MB or 
cTnI, which are released slightly later. A delayed 
presentation is likely to have the opposite effect. 
Therefore, the onset of symptoms should be 
used as the reference point when commenting 
on the sensitivity and specificity of the markers 
for the early diagnosis of AMI rather than 
criteria such as time of presentation, and time of 
admission.10 
2. Size of infarct: Cardiac markers are released 
in proportion to the volume of myocardium in 
jeopardy, the bigger the infarct the greater the 
quantity of cardiac markers released. This will 
lead to improved sensitivity compared to small 
infarcts where a limited release of markers may 
be close to the threshold for detection.11 
3. Selection criteria and prior probability of 
acute myocardial infarction: Selecting certain 
group(s) of patients for the study with a high 
possibility of AMI, such as those admitted to the 
CCU, can also influence sensitivity of a marker.
4. Treatment: Treatment can have an influence 
on the sensitivity  of the marker.  For 
example, patients who have been successfully 
thrombolysed show a greater and earlier peak 
of some of the markers compared to those who 
were not successfully reperfused.12
5. Diagnostic threshold: The selection of an 
appropriate diagnostic threshold requires 
careful consideration of concentrations seen 
in the normal and disease free population 
and those seen in diseased populations. There 
is always a continuous balance between the 
sensitivity and specificity of any marker. If the 
cut-off concentration used is low, the sensitivity 
is improved at the expense of specificity unless 
the marker is 100% cardiac specific, and only 
present in diseased populations.13 
6. Kinetic factors: Kinetic factors like the molecular 
size of the marker, the biological compartment of 
the marker (i.e. whether it exchanges freely in the 
cytoplasm or is attached to structural elements 
within the cell), the volume of distribution, and 
whether the marker is released directly into the 
blood or cleared by the lymphatic system can 
all influence plasma concentration. Markers 
that have a low molecular weight, lie free in 
the cytoplasm, and are released directly into 
the circulation show better early sensitivity 
compared with larger molecules that are 
attached to structural elements and/or cleared 
slowly by the lymphatic system.14
It is not surprising therefore that different studies 
report differing results for sensitivity and specificity 
for the various cardiac markers for the early 
diagnosis of AMI. The variations in the reported 
results will predominantly be influenced by the 
above factors. This review article will discuss 
the currently available markers of myocardial 
damage like creatine kinase (CK), CK muscle and 
brain (MB) (mass and activity), CK-MB isoforms, 
heart-type fatty acid-binding protein (H-FABP), 
myoglobin, cardiac troponin T (cTnT) and  cTnI. The 
discussion will focus in particular on the suitability 
of these markers as tools for: 1) the early diagnosis 
of MI within 6 hours; 2) their ability to detect 
myocardial damage during ischaemic episodes in 
patients with Non-ST elevation MI or undergoing 
cardiac intervention like PCI or surgery; 3) their 
ability to guide further treatments i.e. antiplatelets, 
antithrombotics, coronary interventions, etc; 4) 
their ability to detect reperfusion and re-infarction; 
5) their specificity and limitations and 6) future 
directions with these markers. For the sake of clarity, 
unstable angina with elevated cardiac markers 
quoted in various references in the literature will 
be used synonymously with Non-ST elevation MI 
using the recent new definition of acute coronary 
syndromes referred to above.4
Creatine Kinase  
Creatine kinase is an enzyme composed of two 
subunits, M and/or B. Three different pairs of 
these units combine to give rise to three different 
isoenzymes, CK-BB, CK-MB and CK-MM. CK-
BB is the brain isoenzyme and is present in large 
quantity in the brain and many internal organs. CK-
MB is the heart specific isoenzyme and has been 
the gold standard method for the diagnosis of AMI 
in many laboratories. It exists in large quantity in 
heart muscle, but is not totally cardiac specific and 
exists also in skeletal muscles and other tissues. 
Cardiac markers in the Early Diagnosis and Management of Patients with Acute Coronary Syndrome
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About 15-40% of the total CK activity of heart 
muscle is due to CK-MB, the rest is largely due to 
the CK-MM isoenzyme. CK-MM is the skeletal 
muscle isoenzyme. It has the highest distribution in 
skeletal muscles. The three isoenzymes are present 
in varying concentrations in the smooth muscle of 
the colon, ileum, stomach, and urinary bladder.15 
The reference range for CK is approximately 80-200 
IU/L for men and 60-140 IU/L for women. This is 
the result of the normal turnover of this enzyme in 
skeletal muscles, and it is influenced by factors like 
muscle mass and physical work.
creatine kinase and acute 
myocardial infarction
Creatine kinase was introduced in 1965 as a 
biochemical marker for myocardial damage and it 
is one of the oldest markers in this field.16 It has a 
clinical sensitivity for the diagnosis of AMI of 90%. 
Unfortunately, this is not matched by high specificity. 
It is released within 12 hours after symptom onset 
of AMI, peaks in serum at 24-36 hours, and returns 
to normal in 48-72 hours. As a result of these release 
kinetics, measurement of total CK is not suitable 
for the early diagnosis (within 6 hours) of AMI. 
CK as a marker is also unsuitable for the detection 
of myocardial damage that may occur in patients 
presenting with Non-ST elevation MI, or in patients 
undergoing PCI or surgery. As mentioned earlier, 
a marker that is suitable for the early diagnosis 
of AMI, and the detection of small injuries to the 
heart should have: a high cytoplasmic (cell) to 
vascular (plasma) ratio, very low or undetectable 
normal plasma concentration and total cardiac 
specificity. CK does not fulfil these criteria since 
it has a moderate cytoplasmic to vascular ratio of 
60,000:1; a high reference range up to 200 IU/L, 
and is widely distributed in the body. To improve 
on the cardiac specificity of CK for the diagnosis of 
AMI, it was recommended to measure both total 
CK and CK-MB (the cardiac specific isoenzyme of 
CK). A CK-MB to CK ratio of > 6% is reported to 
be specific for myocardial injury, whereas a ratio of 
< 6% is consistent with skeletal muscle damage or 
non-cardiac causes. 
In some clinical settings, a CK-MB test is not 
requested unless the total CK activity is elevated. The 
use of total CK as a screening test before ordering 
CK-MB could miss some patients with AMI and 
should be used with caution. There are cases of AMI 
without elevation of total CK concentration, but the 
total CK-MB fraction and the CK-MB to CK ratio in 
these patients is diagnostic for AMI. This is likely 
to happen in situations when there is a small MI in 
a small sized person with a low muscle bulk, and a 
low baseline value of total CK. The normal reference 
range of CK is very broad and these patients could 
release small amounts of the enzyme, insufficient to 
raise the concentration above the reference range. If 
this possibility is not borne in mind, the diagnosis 
could be missed when CK is used. Unless the 
baseline total CK is known in a patient presenting 
with highly suspicious diagnosis of ischaemia, a 
low total CK should not exclude the diagnosis nor 
should it preclude requests for CK-MB.10 
limitations and future direction 
of creatine kinase measurement
The CK enzyme is widely distributed and there are 
various causes of elevated total CK in the absence of 
myocardial injury.17 Haemolysis leads to the release 
of the adenylate kinase enzyme, which interferes 
with the assay and causes false elevation of total CK 
activity. Various forms of skeletal muscle injury can 
lead to increased CK activity including strenuous 
exercise, intramuscular injection, rhabdomyolysis, 
burns, and trauma. Chronic muscle diseases like 
polymyositis, dermatomyositis, and myopathy can 
all lead to increased concentrations of CK. Total 
CK activity is a very sensitive indicator of injury to 
skeletal muscles. Drugs like cocaine and alcohol can 
also raise CK concentrations to abnormal values, 
presumably due to the associated myopathy that 
can occur with the use of these drugs. Neurological 
conditions like myasthenia gravis also elevate 
total CK activity. Other miscellaneous conditions 
including pregnancy, hypothermia, and sepsis can 
increase total CK concentrations.18 In many of these 
situations, the activity of CK-MB is also increased, 
giving a ratio of CK-MB to CK that remains below 
the 6% cut-off point required to differentiate 
between skeletal muscle injury and cardiac muscle 
injury.19  Measurement of CK is a relatively cheap 
assay that is widely available. For this reason, total 
CK measurement will probably continue to be 
used as a marker for myocardial injury especially 
in situations such as: 1) absence of cTnI, cTnT, and 
CK-MB assays; 2) patients with unequivocal ECG 
diagnosis of MI where a non-specific marker such 
as CK can be used to confirm the diagnosis, monitor 
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the progress of the patient in hospital and to gauge 
infarct size.
Creatine Kinase Muscle 
Brain Isoenzyme 
The CK-MB isoenzyme has been considered as 
the gold standard for the diagnosis of AMI. It is 
the isoenzyme of CK specific for heart muscle. 
It is measured in serum or plasma by one of two 
methods: 1) CK-MB activity: this measures the total 
activity of the enzyme in serum/plasma by methods 
like electrophoresis, column chromatography, 
immunoinhibition or immunoprecipitation. The 
results are reported as IU/L. These methods are 
non-specific, measure only active enzymes, and 
have a low analytical sensitivity (5 IU/L); 2) CK-
MB mass: this measures the protein mass in serum/
plasma using specific antibodies against the M, B or 
MB subunits. The results are reported in ng/ml or 
µg/l. These assays are highly specific and have a high 
analytical sensitivity (0.3ng/ml) and can measure 
both active and inactive enzymes. The reference 
ranges using various methods have been reported 
to be 8-16 IU/L for CK-MB activity, and 5-10 ng/ml 
(µg/l) for CK-MB mass.10
creatine kinase-mb activity 
versus creatine kinase-mb mass
Different groups have reported that measurement 
of CK-MB using mass is better than that measuring 
CK-MB activity.20 The recent guidelines for the 
redefinition of AMI recommend the use of CK-MB 
mass as opposed to CK-MB activity.4 The problems 
inherent in measuring activity are: 
1.  The enzyme may become deactivated by 
experimental manipulations leading to a low 
value or underestimation. This is likely to 
happen in the low range of CK-MB activity 
such as in patients with small AMI or with 
minor myocardial damage. In an extreme 
situation, a false negative result could result in 
the missed diagnosis of AMI. Unlike CK-MB 
activity assays, CK-MB mass assays measure 
both active and inactive enzyme.
2. In haemolysed blood samples, interference 
from adenylate kinase, an enzyme released 
from red blood cells which catalyses the 
same reaction as CK-MB, could result in false 
positive results. This problem is irrelevant with 
mass assays because the antibodies are specific 
for the CK-MB and the presence of adenylate 
kinase has no effect on the assay.17
3. Creatine kinase-MB measurement using mass 
has better early sensitivity for the diagnosis of 
ST elevation AMI. It has also been reported to 
be more sensitive in detecting small injuries to 
the myocardium that occur in patients with 
non-ST elevation ACS.21 
4.  The presence of CK-BB, macro CK Type 1, 
or macro CK Type 2 in high concentrations 
could interfere with the result and lead to false 
elevation of CK-MB when activity measurement 
is used. These interferences have no such 
effects when mass assays are used because the 
antibodies are specific for CK-MB and do not 
cross-react with these compounds.22 
creatine kinase-mb and st 
elevation myocardial infarction
Creatine kinase MB follows the same release 
kinetics as CK and has a sensitivity and specificity 
for the diagnosis of AMI of more than 90%. This 
sensitivity and specificity changes with the time of 
presentation after symptom onset. Measurement of 
CK-MB activity is most reliable in the 12-24 hours 
period after symptom onset.23 A negative result 
earlier than 12 hours from the start of symptoms 
is too early to rule out AMI, and a negative result 
after 24 hours may be too late. Studies comparing 
the utilisation of these assays for the early diagnosis 
of AMI have shown that CK-MB mass reaches 
the cut-off point in serum several hours before 
CK-MB activity and have claimed its superiority 
within 4-8 hours after symptom onset.21 The CK-
MB mass assay has been shown to be sensitive for 
the diagnosis of AMI even in situations where the 
ECG is equivocal and can increase the number of 
diagnoses made within the time scale required for 
the administration of reperfusion treatment.24 
creatine kinase-mb and non-st 
elevation mi
Creatine kinase MB activity tends to be normal 
in patients with Non-ST elevation MI, whereas 
CK-MB mass is increased in a proportion of these 
patients. This observation has been substantiated 
by different groups.25 A study by Seo et al. in 1993 
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compared CK-MB mass versus CK-MB activity and 
concluded that CK-MB mass is more sensitive when 
CK-MB concentration is in the low range.26 This is 
important especially in cases of myocardial injury 
in Non-ST elevation MI, following complicated 
PCI, and in radiofrequency ablation of arrhythmias 
when the amount of CK-MB released can be small. 
Sensitive CK-MB mass assays can detect prolonged 
ischaemia in Non-ST elevation MI and have been 
used for risk stratification in these patients. One 
small study has shown a very high death rate (64%) 
during four years follow-up in patients who were 
admitted to the CCU with chest pain, positive CK-
MB mass, and non-diagnostic ECG changes of 
ST elevation MI.27 Several investigators have also 
studied the release of CK-MB mass following PCI.28 
They demonstrated that CK-MB mass is a sensitive 
indicator of myocardial injury following PCI. 
One study reported that 40% of patients showed 
evidence of myocardial damage following PCI using 
both CK-MB mass and cTnT.29 
limitations and future direction 
of creatine kinase-mb assays
Creatine kinase MB measurement is not totally 
specific for MI and there are various causes 
for elevated CK-MB concentrations other than 
AMI.17 Cardiac pathologies like congestive cardiac 
failure and arrhythmia lead to elevated CK-MB 
concentration. Severe skeletal muscle damage e.g. 
acute muscle trauma, skeletal muscle disorders 
like myositis, polymyositis, chronic inflammatory 
and degenerative muscle disorders can lead to 
CK-MB elevation. In these situations, the CK-MB 
to CK ratio or cardiac troponins can be used to 
differentiate cardiac and non-cardiac pathologies.30 
Measurement of CK-MB is a widely accepted assay 
that is both sensitive and relatively specific for 
the detection of AMI. However, CK-MB (activity 
or mass) is not sufficiently sensitive in the first 6 
hours after symptom onset for the early diagnosis 
of AMI.4
creatine kinase muscle brain 
isoforms (subforms)
Creatine kinase MB isoforms are variants of the CK-
MB isoenzyme, which result from post-synthetic 
modification of the M subunit. They were discovered 
by Weavers in 1972.31 After ischaemic damage to 
the heart, the CK-MB isoenzyme is released from 
the damaged heart muscle into the blood. This 
isoenzyme is converted into other forms by the 
action of the plasma enzyme carboxypeptidase N 
(CPN) according to the following reaction: 32                       
 
CK-MB2 (tissue form)  CPN (-Lysine)  CK-
MB1 (plasma form) 
In this reaction, the CPN enzyme removes one 
lysine amino acid from the M subunit of the released 
CK-MB2 to produce CK-MB1. CK-MB2 and CK-
MB1 exist in equilibrium (1:1 ratio) in the serum of 
normal healthy people. Therefore, measurement of 
total CK-MB at any point in time is equivalent to 
50% CK-MB2 and 50% CK-MB1. 
Most assays that measure CK-MB use a relatively 
high upper limit of reference range (10ng/ml, 14 
IU/L). Humans differ in their background level 
of CK-MB and some people may express normal 
concentrations as low as 1-2 IU/L (or ng/ml). 
Therefore, in the event of myocardial injury, it will 
require a several-fold increase in the marker before 
it exceeds the upper limit of the reference range. 
CK-MB, being a relatively large molecule, may take 
even longer to reach the circulation and become 
important diagnostically. When myocardial injury 
occurs, there is a sudden release and rise of the tissue 
isoforms, i.e. CK-MB2 compared to the plasma form 
CK-MB1, leading to a rise in the ratio of CK-MB2 
to CK-MB1. By using CK-MB isoforms effectively 
each patient acts as his own control, and a release 
of only a small amount of the marker is required to 
raise the ratio much earlier to a significant level. The 
requirement for the diagnosis of AMI is two-fold: 1) 
increase of CK-MB2 > 2.6 IU/L and 2) increase of 
CK-MB2 to CK-MB1 ratio > 1.7.
creatine kinase-mb isoforms and 
acute myocardial infarction
Creatine kinase MB isoforms are reported to be 
released within 1 hour after symptom onset and 
peak at 4 hours. Evidence of AMI can be detected 
as early as 1-2 hours post-infarction, several hours 
before total CK-MB reaches diagnostic level.33 
These release kinetics make CK-MB isoforms 
potential markers for the early diagnosis of AMI. 
The sensitivity and specificity of CK-MB2 to CK-
MB1 ratio for the diagnosis of AMI was reported 
to be 92% and 95% respectively within 6 hours of 
infarction.34 During this time interval, total CK-MB 
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mass or activity would just be approaching the upper 
limit of the reference range. One study reported 
a sensitivity and specificity of 95.7% and 93.9% 
respectively with a high positive predictive value 
and a high negative predictive value within 6 hours 
of infarction. A total of 114 out of 118 patients 
with AMI were identified using CK-MB isoforms 
within 6 hours. The sensitivity and specificity of 
conventional CK-MB during this time interval was 
48% and 94% respectively.35 Seventeen patients who 
were discharged from the emergency department 
fulfilled the criteria for the diagnosis of AMI using 
CK-MB isoforms (missed diagnosis). The test 
was also positive in patients with hypothyroidism 
and rhabdomyolysis.35 These findings were also 
substantiated by other studies.36 
Some investigators however, have questioned 
the value of CK-MB isoforms for the early diagnosis 
of AMI. A study by Laurino et al. in 1996 showed 
no difference between CK-MB isoforms and 
conventional CK-MB isoenzyme at 6 hours after 
symptom onset.37 Another study by Bhayana et 
al., using comparison between CK-MB mass, CK-
MM3 to CK-MM1 ratio, and CK-MB2 to CK-MB1 
ratio found no significant advantage of isoforms 
over CK-MB mass for the diagnosis of AMI within 
6 hours.38 
limitations of creatine kinase-
mb isoforms assays
There are still unresolved issues surrounding the 
use of CK-MB isoforms for the early diagnosis 
of MI. There is still some concern regarding the 
stability of these isoforms in serum/plasma after 
their release from damaged tissues.39 There are also 
some reports of possible variations in the activity 
of the CPN enzyme among humans.40 This may 
have a profound effect on the use of the isoforms 
as markers for the early diagnosis of AMI and could 
lead to false positive or false negative results.39 The 
other drawback is that the use of isoforms does not 
obviate the need to analyse total CK and the relative 
index of CK-MB to total CK to exclude false positive 
results.41 
Myoglobin
Myoglobin is a small heme protein (17 K Da) 
that functions in oxygen binding and transport. 
It stores oxygen in red muscles (skeletal and 
cardiac) and, under conditions of severe oxygen 
deprivation, it releases the oxygen to be used by 
muscle mitochondria for synthesis of adenosine 
triphosphate (ATP). The myoglobin content of 
heart muscle is reported to be 2.5mg/g wet weight 
of tissue and the skeletal muscle content is 4.0mg/g 
wet weight of tissue.42 Myoglobin constitutes 2% 
of the total cytosolic protein content of cardiac 
muscle. The reference range of serum myoglobin 
is about 20-80ng/ml. Males have higher levels than 
females because they have bigger body size and 
muscle bulk.
myoglobin and acute myocardial 
infarction
Myoglobin is one of the best available early markers 
of AMI within 3 hours after symptom onset. The 
relationship between AMI and high myoglobin 
levels was first reported in 1975.43 Myoglobin starts 
to increase in blood within 2 hours after symptom 
onset of AMI, peaks at 6-9 hours, and returns to 
normal within 24 hours. In a study by Bhayana in 
1994, myoglobin was found to be superior to CK-
MB mass and TnT for ruling out AMI within the 
period of 3-6 hours after symptom onset.44 This 
early release feature of myoglobin is attributed to 
its small size and localisation within the cytosol 
of the cell. Several investigators have confirmed a 
significant role for myoglobin in the early diagnosis 
of AMI, the most promising role being in the early 
exclusion of AMI in patients presenting within 6 
hours after symptoms onset.45  Within this period, 
the overall diagnostic sensitivity and specificity 
ranged from 77-97% and 90-97.9% respectively. 
The variation in sensitivity depends mostly on 
the time of presentation after symptom onset and 
drops considerably with very early (< 2 hours) or 
late presentation (> 15 hours) to the hospital.11 A 
consistently negative result within this time interval 
has such a high negative predictive value for ruling 
out AMI that confident decisions regarding patients’ 
management can be based on it. However, a positive 
result should be used with caution, as there are 
many situations that could give rise to myoglobin 
elevation in the absence of AMI.46 
limitations of myoglobin 
measurement 
Myoglobin is a non-specific marker protein for 
myocardial injury. Serum myoglobin is raised in 
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skeletal muscle damage including intramuscular 
injection, exhaustive exercise, muscle trauma, 
direct current shock cardioversion, and also in 
patients and carriers of genetic muscle disease. 
Severe renal disease leads to failure of clearance of 
myoglobin from the circulation. The concentration 
tends to rise and the circulation time is prolonged in 
these patients. Although these factors interfere with 
the specificity of the test, in clinical practice most 
of them could be ruled out by careful attention to 
history taking and simple blood tests. The specificity 
is increased when myoglobin measurement is 
combined with other diagnostic methods like ECG 
or more specific cardiac markers like CK-MB, cTnT, 
or cTnI.47 
myoglobin and the detection of 
reperfusion 
Ideally, all AMI patients should be treated with 
intravenous thrombolytic treatment or PCI. The 
success of thrombolytic treatment in establishing 
reperfusion is reported to be 50-80% depending 
on the thrombolytic agent.48 Establishment of 
reperfusion after the initiation of thrombolytic 
treatment is important to clinicians in terms of 
treatment and prognostic implications. Coronary 
angiography is the most definitive method to 
assess the success of thrombolytic treatment, but 
this procedure is invasive, carries morbidity and 
mortality risks, requires a catheterisation laboratory 
team, and is not widely available. Biochemical 
markers like myoglobin (among others) offer 
an alternative non-invasive, safe and potentially 
sensitive method for the detection of reperfusion. 
This can be done by monitoring the changes in 
serum concentration immediately before and 60 or 
90 minutes after initiation of thrombolysis. Patients 
who successfully reperfuse their occluded artery 
show a higher and early concentration peak of the 
biochemical marker compared to those who fail to 
reperfuse.49 Patients with uncomplicated MI who 
reperfuse achieve a peak value of myoglobin at 
1 hour, whereas those who fail to reperfuse reach 
peak value about 5 hours later.50 A two-fold increase 
in myoglobin concentrations within 60 minutes 
compared to the base line pre-thrombolysis value 
is associated with 95% predictive accuracy for 
the detection of reperfusion.51 The existence of 
“no-reflow” is an important indicator of impaired 
reperfusion and functional recovery. Thus a patent 
artery does not invariably indicate tissue reperfusion. 
Accurate markers of tissue reperfusion are required. 
The combination of serial 12-lead ECG, clinical 
features, and serial cardiac markers testing offer a 
practical alternative to coronary angiography for 
assessment of reperfusion status.
Heart-type (H-FABP) Fatty 
Acid-Binding Protein
Heart-type fatty acid binding protein (H-FABP) is 
a small (15 Kda) soluble non-enzyme protein. It is 
composed of 132 amino acids. It is one of the most 
abundant proteins in the heart and comprises 5-15% 
of the total cytosolic protein pool in the aqueous 
cytoplasm. It was introduced by Glatz et al. in 1988 
as a potential novel biochemical marker for the 
early diagnosis of AMI;52 this was soon confirmed 
in other studies.53-54 Under normal conditions, 
H-FABP is not present in plasma or interstitial fluid, 
but is released into the blood upon cardiac cellular 
injury. The cytoplasmic to vascular concentration of 
H-FABP is of the order of 200,000:1.55 The plasma 
or serum concentration of H-FABP under normal 
conditions is < 5µg/L. This makes the plasma 
estimation of H-FABP a suitable indicator for the 
early detection and quantification of myocardial 
tissue injury. 
h-fabp and acute myocardial 
infarction
Heart-type FABP is released into plasma within 2 
hours after symptom onset and is reported to peak 
at about 4-6 hours and to return to normal base 
line level in 20 hours.55 Within the period of 30-
210 minutes after symptom onset, H-FABP has > 
80% sensitivity for the diagnosis of AMI.56 Within 
the interval of 0-6 hours after symptom onset, the 
other cardiac markers such as CK, CK-MB (mass 
or activity), I cTnI and cTnT will only be starting to 
accumulate in the plasma, and their sensitivity has 
been reported to be around 64%.57 A rise in serum 
and urine H-FABP concentration above reference 
values is seen in patients presenting with AMI 
as early as 1.5 hours after symptom onset. Serial 
measurements of H-FABP in the first 24 hours after 
onset of symptoms may be potentially useful for: 
the diagnosis of AMI; to identify patients who need 
early reperfusion treatment; to identify patients 
who reperfuse their infarct related artery; to detect 
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re-infarction if it occurs early and for estimation 
of infarct size.58 However, some of the more recent 
studies have questioned the value of these early 
markers (H-FABP and myoglobin) when compared 
with specific markers like cTnI.59-60
limitations and future directions 
of h-fabp measurements
Heart-type FABP exists in high concentrations in 
the heart only. However, this protein is not totally 
cardiac specific and occurs in other tissues although 
in much lower concentrations.57 It is present in 
skeletal muscles in concentrations varying between 
0.05-0.2 mg/g wet weight of tissue, depending on the 
muscle fibre type studied.61 It has also been reported 
in very low concentrations in tissues like the kidney, 
aorta, testes, mammary glands, placenta, brain, 
adrenal glands, adipose tissue, and stomach.57
Heart-type FABP is secreted by the kidney and 
circulates for a longer time (> 25 hours) after AMI in 
the presence of renal failure. Gorski et al. reported 
that H-FABP and myoglobin concentrations were 
both significantly elevated in patients with renal 
failure. The concentrations of these markers were 
not affected by dialysis.62 We have also shown that 
the efficiency of H-FABP for the diagnosis of AMI 
is severely limited in patients with renal failure.63 
Skeletal muscle damage during the course of AMI, 
e.g. intramuscular injections, electric cardioversion 
and traumatic cardiopulmonary resuscitation, may 
result in the leakage of H-FABP and this could 
interfere with the results of the assays.64 Diagnosis 
of AMI in these groups of patients using H-FABP 
alone can be difficult. H-FABP is increased in 
the plasma of healthy volunteers after strenuous 
exercise.65 Surgery (both cardiac and non-cardiac) 
causes elevation of H-FABP concentration. 
h-fabp and myoglobin
Myoglobin and H-FABP share many key features: 
1) low molecular weight proteins (17 and 15Kda, 
respectively); 2) abundant concentrations in 
the cytosol of myocardial cells; 3) substrate for 
mitochondrial oxidation (oxygen and fatty acids, 
respectively and  4) both are released within 2 
hours after symptom onset, peak early (6 hours) 
and return to normal baseline concentration within 
24 hours. Both proteins are present in the heart 
and skeletal muscle in different concentrations. The 
concentration of myoglobin in heart and skeletal 
muscle is 2.5 and 4.0mg/g wet weight of tissue, 
respectively. The H-FABP concentration in heart and 
skeletal muscle is 0.5 and 0.05-0.2 mg/g wet weight 
of tissue, respectively. The myoglobin content of 
skeletal muscle is twice that of the heart. The H-FABP 
content of skeletal muscle is only 10-50% of that 
of the heart. The normal plasma concentration of 
H-FABP (< 5µg/L) is 10 to 15-fold lower than that of 
myoglobin (30-80µg/L). H-FABP is therefore more 
cardio-specific than myoglobin. The normal ratio of 
myoglobin: H-FABP in the myocardium is about 1:5, 
whereas the ratio in skeletal muscle is in the order 
of 21:70 (depending on muscle type).66 The main 
disadvantage of myoglobin and H-FABP as early 
markers of myocardial injury is their lack of total 
specificity due to their presence in skeletal muscle. 
Because both proteins are released into plasma after 
injury at about the same time and in a ratio similar 
to the protein’s concentration in the tissue of origin, 
the measurement of the myoglobin: H-FABP ratio 
could be a useful index for discrimination between 
cardiac and skeletal muscle damage. A myoglobin: 
H-FABP ratio that is around 1:5 is considered to 
be specific for the heart and a ratio that is between 
21:70 is more specific to skeletal muscle damage.64 
The ratio has been reported by some investigators to 
increase the diagnostic specificity for the diagnosis 
of AMI more than relying on either marker alone. 
However, the use of this ratio should not be a rigid 
criterion as overlaps do occur. Some investigators did 
not support additional value over the measurement 
of H-FABP alone.64,67
Cardiac Troponins
The troponin complex is found on the thin filament 
(actin) of all types of striated muscle (fast, slow, 
and cardiac). Its function is to regulate calcium 
dependent contraction of muscles. There are three 
types of troponins: TnT, TnI and TnC. They are 
designated with a letter that refers to the function 
of the troponin protein; TnC binds calcium; TnI 
inhibits the action of the enzyme actomyosin 
adenosine triphosphatase; TnT binds to 
tropomyosin.68 They are called isoforms and have a 
pre-fix to indicate the muscle type they are in e.g. 
cTnT, sTnT, fTnT stand for cardiac muscle, slow 
twitch skeletal muscle, and fast twitch skeletal 
muscle TnT respectively. Cardiac TnT has more 
tissue distribution and more free cytoplasmic 
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concentration and is released as a complex with 
the other cardiac troponin T-I-C. Cardiac TnI is 
released more in the binary form (troponin I-C 
complex).69 Each troponin protein within these 
muscles has a different molecular weight, different 
amino acids, and an amino acid sequence unique to 
that muscle type. The different isoforms of TnT and 
TnI share between 40-55% of amino acid sequence 
homology.70 
cardiac troponin t and acute 
myocardial infarction
Cardiac-TnT (34 KDa) was first introduced in 1989 
as a marker for AMI.71 The upper limit for cTnT 
has been reported as < 0.1µg/L, but concentrations 
between 0.03-0.1µg/L may also have significance 
as markers of an adverse outcome.72 Cardiac-TnT 
appears in the serum within 12 hours after symptom 
onset in patients with AMI. It shows similar release 
kinetics to CK-MB and cTnI, and thus does not 
provide an earlier detection for AMI than CK-
MB or cTnI within the first 6 hours after symptom 
onset.73 Once in the circulation, it persists for a long 
time (2-3 weeks) after symptom onset. The half-
life of cTnT in circulation is 120 minutes and this 
long diagnostic window is thought to be due to the 
continuous release of the marker from myocardial 
cells after necrosis, and not due to slow clearance 
from the circulation.74 The clinical sensitivity of 
cTnT for the diagnosis of AMI approaches 100% at 
about 12 hours after symptom onset and remains 
elevated at 100% for at least 4 days.74 
unstable angina and increased 
cardiac troponin t (non-st 
elevation mi) 
Unstable angina/Non-ST elevation MI carries 
significant morbidity and mortality risks and early 
detection and treatment are essential to minimise 
complications.75 Cardiac-TnT has been shown 
to be elevated in patients with Non-ST elevation 
MI and the magnitude of elevation can be used 
for diagnostic purposes, risk stratification, and 
for selection of appropriate patient groups for 
treatment. Elevated cTnT in patients with Non-ST 
elevation MI is associated with poor prognosis.76 The 
increase correlates well with the severity of coronary 
artery lesions determined by angiography.77 In one 
important study, the prognostic value of cTnT 
was assessed in 967 patients with unstable angina. 
It was found that the group that had elevated 
concentrations of cTnT had an increased risk of 
cardiac events and the higher the cTnT the more 
frequent the complications. Patients were followed-
up for 6 months for cardiac complications. The risk 
of further AMI and death was 4.3% in patients with 
cTnT less than 0.06µg/L and 16.1% for those with 
cTnT equal or greater than 0.18µg/l.78 In another 
study by Stubbs et al., 62 Non-ST elevation MI 
patients were followed-up for about three years after 
their admission with cTnT concentration greater or 
equal to 0.2 ng/ml. The incidence of complications 
in this group was very high: cardiac death (12 
patients), coronary revascularisation (22 patients), 
death and non-fatal AMI (18 patients).79 
Cardiac-TnT measurement can help select 
the appropriate patients for treatment with 
antithrombotics. Treatment of Non-ST elevation 
MI patients with thrombolytic therapy had not been 
found to be useful.80 However, treatment of Non-ST 
elevation MI with antiplatelet and antithrombotic 
drugs like aspirin, clopidogrel, low molecular 
weight heparin (LMWH) and glycoprotein IIb/IIIa 
(GP IIb/IIIa) receptor antagonist was associated 
with 30% reduction in the incidence of mortality 
and AMI.81 Those patients with cTnT < 0.1 ng/
ml fared equally well whether they were treated 
by LMWH, deltaparin or a placebo (4.7 versus 
5.7% x 40 day mortality respectively). However, 
patients with cTnT greater than or equal to 0.1ng/
ml had reduced AMI and mortality if they received 
deltaparin rather than a placebo (7.4 versus 14.2% 
respectively).82-
specificity of cardiac troponin t 
assays 
Elevated cTnT concentration has been reported 
in a significant numbers of patients with chronic 
renal failure. These levels do not seem to be affected 
by haemodialysis, with elevations persisting after 
treatment.83 In chronic kidney disease patients on 
haemodialysis without acute coronary syndrome, 
cTnI was reported to have better sensitivity and 
specificity for the diagnosis of AMI compared 
with cTnT, but positive cTnT was associated with 
increased all cause mortality during follow 
up.84-85 Vigorous exercise, e.g. marathon runners; 
rhabdomyolysis; inflammatory muscle disease, 
e.g. polymyositis and dermatomyositis, and 
degenerative muscle disease, e.g. Duchenne/Becker 
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muscular dystrophy, have been reported to show 
elevated concentrations of cTnT.86 High cTnT 
and cTnI concentrations have been reported in 
critically ill patients who had not been diagnosed 
with comorbid AMI.87 Blunt trauma to the chest, 
closed heart massage, external defibrillation is also 
reported to result in elevation of cTnT.88 Elevations 
have also been reported in cases of myocarditis and 
drug induced cardiac toxicity.89,90 Elevated troponin 
levels (I  and  T) occur  in  some  patients with acute 
pulmonary embolism and this elevation has been 
associated with  a high risk of short-term death and 
an adverse outcome events.91 The advantage of the 
cTnT immunoassay is that currently it is marketed 
by one source only hence there are well-established 
standards in terms of reference range, detection 
limits, and clinical cut-off concentrations. There is 
however, a slightly higher rate of positive results 
with cTnT assays in some patients with chronic renal 
failure and acute or chronic muscle disease.86,92 
cardiac troponin i and acute 
myocardial infarction
Cardiac-TnI (24 KDa) is reported to have a 
unique segment containing 31 amino acids that 
makes it different to either sTnI or fTnI (19 KDa). 
During foetal development both sTnI and cTnI are 
expressed in the myocardium; however, at birth, 
the cTnI remains as the only isoform present in 
the human myocardium.93 Cardiac-TnI has not 
been shown to be expressed in any type of skeletal 
muscle during either development or disease 
stimuli.94 This makes cTnI 100% specific for the 
myocardial tissue and an excellent marker for the 
detection of myocardial injury in serum. Cardiac-
TnI was first reported as a biochemical marker of 
myocardial injury in 1992 and has since been shown 
to be a very sensitive and specific marker for the 
diagnosis of AMI. It has similar release kinetics to 
CK-MB and to cTnT and does not provide an earlier 
detection for AMI within the first 6 hours after 
symptom onset.95 Cardiac-TnI peaks between 12-
36 hours after onset of AMI and remains elevated 
for 3-7 days after AMI. The half-life of cTnI is < 2 
hours and the prolonged diagnostic window is due 
to the continuous release of this marker from the 
myofibril. 
cardiac troponin i and non-st 
elevation mi
Cardiac-TnI is cardiac specific and its concentration 
in normal and disease free populations is 
undetectable or very low. This makes it a suitable 
marker for the detection of myocardial injury in 
patients with Non-ST elevation MI as well as other 
situations where myocardial injury is expected, but 
the amount released could be small, e.g. following 
PCI.96 Many studies have also shown cTnI to 
have prognostic value in patients with non-ST 
elevation MI similar to that of cTnT. Those patients 
showing higher levels at admission have more 
complications increased mortality and AMI on 
subsequent follow-up.97 The prognostic risk in these 
patients is significantly altered if early intervention 
(pharmacological and invasive) is undertaken in 
these patients compared to conservative treatment.
specificity of cardiac troponin i 
assays
Cardiac-TnI was not found in patients who 
underwent uncomplicated angioplasty.98 In patients 
with chest trauma, cocaine associated chest pain, 
and hypothyroidism where CK and CK-MB were 
elevated, cTnI was able to distinguish true myocardial 
injury from cases with false elevation. In marathon 
runners, more than 80% of samples were positive 
for CK-MB and in all of these samples cTnI was 
negative. Cardiac-TnI was found to be significantly 
elevated (43%) in patients with bacteraemia.99 The 
main problem with cTnI is that there are several 
commercial assays available, and each assay differs 
with respect to reference range, detection limit, and 
medical decision cut-off limits. Thus, there is a lack 
of standardisation of methodology for cTnI assays. 
However, cTnI has been reported to show slightly 
better specificity in situations where there is severe 
skeletal muscle injury and renal failure.84,85
specificity of cardiac troponins 
following surgery
Cardiac-TnI was not elevated in patients who 
underwent non-cardiac surgery, but was raised in 
patients undergoing CABG due to surgical injury of 
the myocardium. Cardiac-TnI or cTnT may be the 
preferred markers of choice to detect myocardial 
injury in patients who undergo non-cardiac surgery. 
In the situation of non-cardiac surgery, cTnI (or 
cTnT), being specific to the myocardium, will also 
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help to distinguish elevation of CK-MB due to 
skeletal muscle damage alone from elevation due to 
myocardial injury.100 
Conclusion
The markers that are well suited for the early 
diagnosis of AMI within the time interval 0-6 hours 
after symptom onset are myoglobin, H-FABP and 
CK-MB isoforms. Although all have been shown to 
be excellent sensitive early markers, there are still 
significant issues concerning its specificity. H-FABP 
is more cardio-specific than myoglobin and the use 
of H-FABP as a marker for the early diagnosis of 
AMI seems preferable. CK-MB mass measurement 
is suitable in the 6-24 hours interval; CK-MB based 
on activity measurement is more sensitive in the 
12-24 hours interval, and the other cardiac markers 
like total CK, cTnT, and cTnI are most reliable after 
12 hours from symptom onset. The prolonged 
diagnostic window of cardiac troponins of several 
days that is highly sensitive and specific obviates 
the needs for less specific markers with long 
diagnostic window like aspertate aminotransferase 
(ALT) and CK. Decision-making regarding triage 
and treatment of patients should not be based on 
a single measurement of cardiac markers alone 
because of the time delay required for the marker 
to exceed the upper limit of reference range. Based 
on the recent recommendations by the ESC/
ACC, cTnI and cTnT are the best markers for the 
confirmation of AMI. CK-MB (preferably mass) is 
the second best marker in the absence of troponins 
assays. Patients who present with acute chest 
pain suspicious of ACS  are best managed within 
specifically designated units that have rapid access 
to specific equipment (ECG, echocardiogram) and 
facilities (point of care instruments to measure 
cardiac markers), and with appropriate staffing. 
Acute chest pain units attached to emergency 
departments can accommodate patients for 12 
hours, so that appropriate investigations can be 
carried out quickly after presentation in order to 
identify patients with evolving infarction who are 
at increased risk.
A serial combination testing of a sensitive 
early marker (e.g. H-FABP, myoglobin or CK-MB 
isoforms) and one of the cardiac specific troponins 
(cTnT or cTnI) offers the best approach. Two serial 
testings within a minimum of 12 hours (e.g. at 
0 hour, 4-6 hours, or at 12 hours) after symptom 
onset provide reliable sensitivity and specificity for 
detecting ischaemia and evolving infarction within 
the time interval required for the implementation 
of reperfusion therapy. This 12 hour strategy also 
identifies patients at low-risk for acute ischaemic 
events. 
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